[1]
|
[1] C. Rozman, E. Feliu, M. Giralt, D. Rubio and M. T. Cortés, “Life Expectancy of Patients with Chronic Nonleukemic Myeloproliferative Disorders,” Cancer, Vol. 67, No. 10, 1991, pp. 2656-2663.
doi:10.1002/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C
|
[2]
|
F. Girodon, F. Dutrillaux, J. Broséus, M. Mounier, V. Goussot, P. Bardonnaud, et al., “Leukocytosis Is Associated with Poor Survival But Not with Increased Risk of Thrombosis in Essential Thrombocythemia: A Population-Based Study of 311 Patients,” Leukemia, Vol. 24, No. 4, 2010, pp. 900-903. doi:10.1038/leu.2010.5
|
[3]
|
N. Gangat, J. Strand, C.-Y. Li, W. T. Wu, A. Pardanani and A. Tefferi, “Leukocytosis in Polycythemia Vera Predicts Both Inferior Survival and Leukemic Transformation,” British Journal of Haematology, Vol. 138, No. 3, 2007, pp. 354-358.
doi:10.1111/j.1365-2141.2007.06674.x
|
[4]
|
F. Palandri, L. Catani, N. Testoni, E. Ottaviani, N. Polverelli, M. Fiacchini, et al., “Long-Term Follow-Up of 386 Consecutive Patients with Essential Thrombocythemia: Safety of Cytoreductive Therapy,” American Journal of Hematology, Vol. 84, No. 4, 2009, pp. 215-220.
doi:10.1002/ajh.21360
|
[5]
|
N. Gangat, A. P. Wolanskyj, R. F. McClure, C.-Y. Li, S. Schwager, W. Wu and A. Tefferi, “Risk Stratification for Survival and Leukemic Transformation in Essential Thrombocythemia: A Single Institutional Study of 605 Patients,” Leukemia, Vol. 21, No. 2, 2007, pp. 270-276.
doi:10.1038/sj.leu.2404500
|
[6]
|
J. J. Kiladjian, C. Gardin, M. Renoux, F. Bruno and J. F. Bernard, “Long-Term Outcomes of Polycythemia Vera Patients Treated with Pipobroman as Initial Therapy,” The Hematology Journal, Vol. 4, 2003, pp. 198-207.
doi:10.1038/sj.thj.6200250
|
[7]
|
G. Finazzi, V. Caruso, R. Marchioli, G. Capnist, T. Chisesi, C. Finelli, et al., “Acute Leukemia in Polycythemia Vera: An Analysis of 1638 Patients Enrolled in a Prospective Observational Study,” Blood, Vol. 105, No. 7, 2005, pp. 2664-2670. doi:10.1182/blood-2004-09-3426
|
[8]
|
P. Guglielmelli, G. Barosi, L. Pieri, E. Antonioli, A. Bosi and A. M. Vannucchi, “JAK2V617F Mutational Status and Allele Burden Have Little Influence on Clinical Phenotype and Prognosis in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis,” Haematologica, Vol. 94, No. 1, 2009, pp. 144-146.
doi:10.3324/haematol.13721
|
[9]
|
G. Barosi, G. Bergamaschi, M. Marchetti, A. M. Vannucchi, P. Guglielmelli, E. Antonioli, et al., “JAK2V617F Mutational Status Predicts Progression to Large Splenomegaly and Leukemic Transformation in Primary Myelofibrosis,” Blood, Vol. 110, No. 12, 2007, pp. 4030-4036.
doi:10.1182/blood-2007-07-099184
|
[10]
|
F. Passamonti, E. Rumi, D. Pietra, C. Elena, E. Boveri, E. Roncoroni, et al., “A Prospective Study of 338 Patients with Polycythemia Vera: The Impact of JAK2(V617F) Allele Burden and Leukocytosis on Fibrotic or Leukemic Disease Transformation and Vascular Complications,” Leukemia, Vol. 24, No. 9, 2010, pp. 1574-1579.
doi:10.1038/leu.2010.148
|
[11]
|
J. W. Vardiman, J. Thiele, D. A. Arber, R. D. Brunning, M. J. Borowitz, A. Porwit, et al., “The 2008 Revision of the WHO Classification of Myeloid Neoplasms and Acute Leukemia: Rationale and Important Changes,” Blood, Vol. 114, No. 5, 2009, pp. 937-951.
doi:10.1182/blood-2009-03-209262
|
[12]
|
G. Barosi, R. Mesa, J. Thiele, F. Cervantes, P. J. Campbell, S. Verstovsek, et al., “Proposed Criteria for the Diagnosis of Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Consensus Statement from the International Working Group for Myelofibrosis Research and Treatment,” Leukemia, Vol. 22, No. 2, 2008, pp. 437-438. doi:10.1038/sj.leu.2404914
|
[13]
|
M. A. Elliott, S.-Y. Yoon, P. Kao, C.-Y. Li and A. Tefferi, “Simultaneous Measurement of Serum Thrombopoietin and Expression of Megakaryocyte c-Mpl with Clinical and Laboratory Correlates for Myelofibrosis with Myeloid Metaplasia,” European Journal of Haematology, Vol. 68, No. 3, 2002, pp. 175-179.
doi:10.1034/j.1600-0609.2002.01534.x
|
[14]
|
S. Murphy, P. Peterson, H. Iland and J. Laszlo, “Experience of the Polycythemia Vera Study Group with Essential Thrombocythemia: A Final Report on Diagnostic Criteria, Survival and Leukemic Transformation by Treatment,” Seminars in Hematology, Vol. 34, No. 1, 1997, pp. 29-39.
|
[15]
|
F. Cervantes, A. Alvarez-Larrán, C. Talarn, M. Gómez and E. Montessart, “Myelofibrosis with Myeloid Metaplasia Following Essential Thrombocythemia: Actuarial Probability, Presenting Characteristics and Evolution in a Series of 195 Patients,” British Journal of Haematology, Vol. 118, No. 3, 2002, pp. 786-790.
doi:10.1046/j.1365-2141.2002.03688.x
|
[16]
|
F. Passamonti, E. Rumi, E. Pungolino, L. Malabarba, P. Bertazzoni, M. Valentini, et al., “Life Expectancy and Prognostic Factors for Survival in Patients with Polycythemia Vera and Essential Thrombocythemia,” The American Journal of Medicine, Vol. 117, No. 10, 2004, pp. 755-761. doi:10.1016/j.amjmed.2004.06.032
|
[17]
|
R. Landolfi, L. Di Gennaro, T. Barbui, V. De Stefano, G. Finazzi, R. M. Marfisi, et al., “Leukocytosis as a Major Thrombotic Risk Factor in Patients with Polycythemia Vera,” Blood, Vol. 109, No. 6, 2007, pp. 2446-2452.
doi:10.1182/blood-2006-08-042515
|
[18]
|
A. Carobbio, E. Antonioli, P. Guglielmelli, A. M. Vannucchi, F. Delaini, V. Guerini, et al., “Leukocytosis and Risk Stratification Assessment in Essential Thrombocythemia,” Journal of Clinical Oncology, Vol. 26, No. 16, 2008, pp. 2732-2736. doi:10.1200/JCO.2007.15.3569
|
[19]
|
F. Passamonti, E. Rumi, L. Arcaini, E. Boveri, C. Elena, D. Pietra, et al., “Prognostic Factors for Thrombosis, Myelofibrosis and Leukemia in Essential Thrombocythemia: A Study of 605 Patients,” Haematologica, Vol. 93, No. 11, 2008, pp. 1645-1651.
doi:10.3324/haematol.13346
|
[20]
|
A. Tefferi, N. Gangat, A. P. Wolanskyj, S. Schwager, A. Pardanani, T. L. Lasho, et al., “20+ yr without Leukemia or Fibrotic Transformation in Essential Thrombocythemia or Polycythemia Vera: Predicts at Diagnosis,” European Journal of Haematology, Vol. 80, No. 5, 2008, pp. 386390. doi:10.1111/j.1600-0609.2008.01038.x
|
[21]
|
T. Barbui, J. Thiele, F. Passamonti, E. Rumi, E. Boveri, M. Ruggeri, et al., “Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study,” Journal of Clinical Oncology, Vol. 29, No. 23, 2011, pp. 3179-3184. doi:10.1200/JCO.2010.34.5298
|
[22]
|
A. P. Wolanskyj, S. M. Schwager, R. F. McClure, D. R. Larson and A. Tefferi, “Essential Thrombocythemia beyond the First Decade: Life Expectancy, Long-Term Complication Rates, and Prognostic Factors,” Mayo Clinic Proceedings, Vol. 81, No. 2, 2006, pp. 159-166.
doi:10.4065/81.2.159
|